Literature DB >> 1081905

Intensity of immunosuppressive therapy and the incidence of Pneumocystis carinii pneumonitis.

W T Hughes, S Feldman, R J Aur, M S Verzosa, H O Hustu, J V Simone.   

Abstract

One hundred and forty-nine children with acute lymphocytic leukemia treated according to a prospective protocol were randomized after induction of remission and central nervous system (CNS) irradiation to receive maintenance chemotherapy with 1, 2, 3, or 4 chemotherapy agents. The incidence of P. carinii pneumonitis (PCP) was 5.0, 2.3, 2.2, and 22.4%, respectively, during the period of maintenance therapy. An additional 31 patients enrolled in the same study were placed in special categories to receive three drugs for maintenance plus supplemental chemotherapy or irradiation because of CNS leukemia on admission, remission failure, ediastinal mass, or generalized lymphosarcoma without bone marrow involvement. The incidences of PCP in these groups were 16.7, 30.0, 35.7, and 0%, respectively, during the period of maintenance therapy.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1081905     DOI: 10.1002/cncr.2820360912

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  30 in total

Review 1.  Infection of immunosuppressed patients.

Authors:  H E Kay
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1979

Review 2.  Echinocandin prophylaxis in patients undergoing haematopoietic cell transplantation and other treatments for haematological malignancies.

Authors:  David J Epstein; Susan K Seo; Janice M Brown; Genovefa A Papanicolaou
Journal:  J Antimicrob Chemother       Date:  2018-01-01       Impact factor: 5.790

Review 3.  Prevention of infection due to Pneumocystis carinii.

Authors:  J A Fishman
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

4.  Pneumocystis carinii pneumonia complicating low dose methotrexate treatment for psoriatic arthropathy.

Authors:  P J Wallis; K S Ryatt; T J Constable
Journal:  Ann Rheum Dis       Date:  1989-03       Impact factor: 19.103

5.  Pneumocystis carinii, Toxoplasma gondii, Cytomegalovirus and the compromised host.

Authors:  F W Ryning; J Mills
Journal:  West J Med       Date:  1979-01

Review 6.  The immunology of parasite infections in immunocompromised hosts.

Authors:  T Evering; L M Weiss
Journal:  Parasite Immunol       Date:  2006-11       Impact factor: 2.280

Review 7.  Cell-mediated immunity and its role in resistance to infection.

Authors:  E J Wing; J S Remington
Journal:  West J Med       Date:  1977-01

Review 8.  Pneumocystis carinii pneumonia.

Authors:  J T Macfarlane; R G Finch
Journal:  Thorax       Date:  1985-08       Impact factor: 9.139

Review 9.  Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients.

Authors:  Martin Rodriguez; Jay A Fishman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

10.  Spontaneous Pneumocystis carinii pneumonia in immunodeficient mutant scid mice. Natural history and pathobiology.

Authors:  J B Roths; J D Marshall; R D Allen; G A Carlson; C L Sidman
Journal:  Am J Pathol       Date:  1990-05       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.